Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers
Information source: St. Joseph's Healthcare Hamilton
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Carcinoma, Renal Cell
Intervention: everolimus (Drug)
Phase: N/A
Status: Active, not recruiting
Sponsored by: St. Joseph's Healthcare Hamilton Official(s) and/or principal investigator(s): Anil Kapoor, MD, FRCSC, Principal Investigator, Affiliation: McMaster University
Summary
This study will gather data on potential biomarkers in the treatment of advanced renal cell
carcinoma (kidney cancer) and investigate their use as indicators of disease response. The
results could eventually enable doctors to match levels of therapy to levels of biomarker on
an individual basis and to increase the chance of disease response in patients. This study
will also test a new paradigm in the treatment approach of advanced kidney cancer by using
the drug everolimus in a neo-adjuvant setting, with the overarching goal of decreasing
cancer recurrence rates and improving patient outcomes and survival.
Clinical Details
Official title: A Pilot Study of Neo-Adjuvant Everolimus in Patients With Advanced Renal Cell Carcinoma Undergoing Definitive Therapy With Radical Nephrectomy, or Cytoreductive Nephrectomy - Analysis of Serum and Tissue Biomarkers
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Response of primary tumor and metastases (if applicable) to everolimus in terms of tumor size and appearance (RECIST imaging response criteria) as determined by CT or MRI
Secondary outcome: Effect of everolimus on blood and tissue biomarker expression (periodic blood testing and tissue samples from baseline renal biopsy and nephrectomy) in and among patients with locally advanced and metastatic disease with respect to baseline values
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- At least 18 years of age and capable of giving informed consent
- Radiological evidence of RCC consisting of: CT scan with stage T2, T3, T3a, T3b, T4,
or any stage T with N1/ 2 and/ or metastatic disease
- Having a nephrectomy and willing to have a kidney biopsy
- ECOG score 0 or 1
- Clear cell histology
- Negative for HIV, Hepatitis B, and Hepatitis C
- Negative pregnancy test for women of child-bearing potential
Exclusion Criteria:
- Stage T1 disease without metastases
- Abnormal laboratory values at screening within the following ranges:
- Absolute neutrophil count ≤ 1. 5 × 109/ L; Platelet count ≤ 100 × 109/ L
- Leukocyte count ≤ 3 × 109/ L; Hemoglobin ≤ 80 g/ L; Serum creatinine ≥ 2. 0 × the
upper normal limit (UNL); Total bilirubin ≤ 1. 5 × UNL; AST and ALT ≤ 3. 0 × UNL
- Fasting serum cholesterol ≤ 9. 0 mmol/ L; Fasting serum triglycerides ≥ 5. 0 mmol/L
- Any major illness that, based on the investigator's judgment, will substantially
increase the risk associated with a subject's participation in this study
- Other currently active malignancies
- Currently taking any medications known to interfere with the metabolism of everolimus
- Receiving anticoagulation with warfarin
- A history of pulmonary hypertension or interstitial lung disease
Locations and Contacts
St. Joseph's Healthcare, Hamilton, Ontario L8N 4A6, Canada
Additional Information
Starting date: October 2010
Last updated: March 17, 2015
|